{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-22-000089","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.928290+00:00","generated_at":"2026-06-21T12:21:58.905291+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allogene releases Phase 1 data across CAR T programs; initiates Phase 2 ALPHA2 trial","bullets":["Single Dose FCA90 in LBCL achieved 67% ORR, 58% CR; 50% in CR at 6 and 12 months. No Grade 3+ CRS or neurotoxicity.","ALLO-715 in MM expansion (FCA60): 67% ORR, 42% VGPR+ (all MRD-negative), median DOR 9.2 months, longest 24 months.","ALLO-316 in RCC CD70+ patients (n=9): 100% disease control, 33% partial responses; generally manageable safety.","Phase 2 ALPHA2 trial enrolling ~100 LBCL patients; planning pivotal Phase 2 for ALLO-715 and evaluating ALLO-316 expansion.","Research update: Dagger technology aims to delay AlloCAR T rejection; ALLO-605 trial paused for manufacturing review."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-22-000089","json":"https://secwatch.observer/filing/0001737287-22-000089.json","markdown":"https://secwatch.observer/filing/0001737287-22-000089.md","text":"https://secwatch.observer/filing/0001737287-22-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000089/0001737287-22-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000089/allo-20221129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:21:58.905291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}